Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties
A machine-learning-guided peptide optimization workflow selected GUB021794, reported at 0.018 nM GLP-1R potency in the paper assay and dose-dependent weight loss in diet-induced obese mice. These preclinical results do not establish human efficacy, safety or a dosing regimen.
Technology: streaMLine machine-learning QSAR analysis integrated with peptide synthesis and screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary abstract reports the named candidate and mouse outcomes; no human clinical result is established.
- Still unknown: Independent replication and exhaustive prior-art review are not established.
- AI role: streaMLine machine-learning QSAR analysis integrated with peptide synthesis and screening
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/38977267/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: Primary source checked for study identity, AI operation, dates, affiliations and the bounded result. PubMed affiliation block names Gubra..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.